Putting hemophilia patients first

yesterday, today, tomorrow

This educational satellite symposium is intended for healthcare professionals.
It is fully organised and paid for by Bayer and will include discussion of Bayer products.

Reaching peaks in individualised care:

Discover Jivi's▼(damoctocog alfa pegol) real world evidence

Wednesday 8th February, 2023 17:15–18:30
Charter Rooms 1–3, Manchester Central Convention Complex

Jivi®, from clinical studies to real world evidence

17:15–17:30	**Opening remarks and new data generation** Mark Reding

Targeting individual patient needs

17:30–17:40	**Younger patients* who have switched from an SHL treatment** Natascha Marquardt
17:40–17:50	**Patients with synovitis** Dario di Minno
17:50–18:00	**Senior patients with comorbidities** Maria Elisa Mancuso

Closing and reflections

18:00–18:10	**Personal experiences with Jivi®** Mark Reding, Natascha Marquardt, Dario di Minno, Maria Elisa Mancuso
18:10–18:30	**Q&A panel** Mark Reding, Natascha Marquardt, Dario di Minno, Maria Elisa Mancuso

* Jivi is licensed for the treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia A (congenital factor VIII deficiency).

Although licenced, Jivi is not currently available in the UK.

PP-JIV-GB-0005
January 2023

Putting hemophilia patients first

yesterday, today, tomorrow

▼**Jivi® (damoctocog alfa pegol) is subject to additional monitoring.** This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel.: 0118 206 3500, Fax.: 0118 206 3703, Email: pvuk@bayer.com

Jivi 250 / 500 / 1000 / 2000 / 3000 IU powder and solvent for solution for intravenous injection (Refer to full SmPC before prescription).
Composition: site specifically PEGylated recombinant human coagulation factor VIII, 250/500/1000/2000/3000 IU/vial (100/200/400/800/1200 IU/ml after reconstitution). *Excipients:* Powder: Sucrose, Histidine, Glycine, Sodium chloride, Calcium chloride dihydrate, Polysorbate 80, glacial acetic acid (for pH adjustment). Solvent: Water for injections. **Indication:** Treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia A (congenital factor VIII deficiency). **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Known allergic reactions to mouse or hamster proteins. **Warnings and Precautions:** Allergic type hypersensitivity reactions are possible. Hypersensitivity reactions could also be related to antibodies against polyethylene glycol (PEG). If symptoms of hypersensitivity occur, patients should be advised to discontinue the use of the medicinal product immediately and contact their physician. The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. A clinical immune response associated with anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect has been observed primarily within the first 4 exposure days. In patients with existing cardiovascular risk factors, substitution therapy with factor VIII may increase the cardiovascular risk. If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered. **Undesirable effects:** *very common:* headache; *common:* hypersensitivity, insomnia, dizziness, cough, abdominal pain, nausea, vomiting, erythema (incl. erythema and erythema multiforme), rash (incl. rash and rash papular), injection site reactions (incl. injection site pruritus/rash and vessel puncture site pruritus), pyrexia; *uncommon:* FVIII inhibition (previously treated patients), dysgeusia, flushing, pruritus.
On prescription only. Although licensed, Jivi is not currently available in the UK.
Marketing Authorisation Holder: Bayer AG, 51368 Leverkusen, Germany.
Date of revision of the underlying Prescribing Information: December 2019

PP-JIV-GB-0005
January 2023